SHUTTLE PHARMACTCLS HLDGS INC Stock Price, News & Analysis

Shuttle Pharmaceuticals (SHPH) has secured a $4.25 million private placement through a securities purchase agreement with an accredited investor. The company will issue 1,180,877 shares of common stock or pre-funded warrants at $3.60 per share, priced at-the-market under Nasdaq rules. The proceeds will support potential acquisitions, marketing, and general corporate purposes. WestPark Capital serves as the exclusive placement agent, with the offering expected to close around June 23, 2025. The securities are offered only to accredited investors and are not registered under the Securities Act of 1933. Shuttle Pharma has agreed to file registration statements for the resale of the shares and warrant-eligible shares.

Shuttle Pharmaceuticals (NASDAQ: SHPH) has announced a 1-for-25 reverse stock split effective June 16, 2025, at 12:01 a.m. ET. The company's common stock will continue trading under the symbol SHPH on the Nasdaq Capital Market with a new CUSIP number 825693401. The split will reduce outstanding shares from 26,210,037 to approximately 1,048,401 and will apply to RSU grants and warrants. Fractional shares will be rounded up to the next whole number. This strategic move aims to maintain Nasdaq listing compliance and strengthen the company's capital structure. Shuttle Pharma, a specialty pharmaceutical company, focuses on developing radiation sensitizers to improve outcomes for cancer patients undergoing radiation therapy.

Shuttle Pharmaceuticals (SHPH) has announced a proposed 25-for-1 reverse stock split to maintain Nasdaq listing compliance. The split will reduce outstanding shares from 26.2 million to approximately 1.05 million shares, pending Nasdaq approval. The action will affect all common stock, including RSU grants and warrants, with fractional shares being rounded up. Shuttle Pharma, a specialty pharmaceutical company, focuses on developing radiation sensitizers to enhance radiation therapy outcomes for cancer patients while minimizing side effects. The reverse split is positioned as a strategic move to strengthen the company's long-term capital structure while ensuring continued Nasdaq listing compliance.

Shuttle Pharmaceuticals Holdings (NASDAQ: SHPH) has appointed George Scorsis as Chairman of the Board of Directors, effective June 4, 2025. Scorsis, who has served as a director since February 2025, brings over 25 years of experience leading companies in regulated industries. His extensive leadership background includes roles as President at Mettrum Health Corp, CEO of Liberty Health Sciences, and Chairman positions at SOL Global Investments, Entourage Health Corp, and AWAKN Life Sciences. Shuttle Pharma is focused on developing radiation sensitizers to enhance cancer treatment outcomes, specifically targeting improved cure rates, patient survival, and quality of life for patients undergoing radiation therapy.

Shuttle Pharmaceuticals (NASDAQ: SHPH) provided a corporate update on its cancer treatment developments. The company reported significant progress in its Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment, achieving nearly 50% enrollment with 84% of patients completing all seven cycles. The drug is being well-tolerated with toxicity no greater than 2 on a 1-5 scale.

The company has expanded its diagnostic capabilities through a research agreement with UCSF for developing PSMA-targeted ligands for cancer theranostics. Shuttle Pharma also filed a provisional patent for "PSMA-Targeted PARP Inhibitor Conjugates." The company strengthened its board with three new directors and reported $4.5 million in cash as of March 31, 2025. Notable management changes include the resignation of CSO Dr. Anatoly Dritschilo and upcoming retirement of VP Regulatory Michael Vander Hoek.

Shuttle Pharmaceuticals (NASDAQ: SHPH) has reached nearly 50% enrollment in the initial randomized portion of its Phase 2 clinical trial for Ropidoxuridine, targeting glioblastoma treatment. The trial has shown promising initial results with the drug being well-tolerated and 84% of enrolled patients completing all seven cycles. The study involves 40 patients randomized into two dose levels (1,200 mg/day and 960 mg/day), with plans to add 14 more patients at the optimal dose. Ropidoxuridine, which has received FDA Orphan Drug Designation, is being developed as a radiation sensitizer for brain tumors. The trial is being conducted across six major medical centers, with final enrollment expected later this year and data readout in 2026. The company targets a significant market opportunity, with an estimated 400,000 US patients receiving radiation therapy for curative purposes annually, expected to grow by 22% over five years.

Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) has announced its participation in the Planet MicroCap Showcase: VEGAS 2025, scheduled for April 23, 2025, at 2:30 PM Pacific Time. Dr. Anatoly Dritschilo, Chairman and Chief Scientific Officer, will present updates on two key initiatives:

1. The ongoing Phase 2 trial of Ropidoxuridine and radiation therapy for glioblastoma patients

2. Developments at Shuttle Diagnostics subsidiary, focusing on pretreatment diagnostic blood tests and imaging agents for prostate cancer patients

The presentation will take place at the Paris Hotel & Casino in Las Vegas, with both in-person and webcast attendance options. The company, founded in 2012 by Georgetown University Medical Center faculty, focuses on improving outcomes for cancer patients through radiation therapy enhancement, developing radiation sensitizers to increase cure rates and improve survival rates.

Shuttle Pharmaceuticals (NASDAQ: SHPH) has filed a provisional patent application with the USPTO for 'PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy.' The company is developing pretreatment diagnostic blood tests for prostate cancer through its Diagnostics subsidiary.

The patent filing involves collaboration with Dr. Alan Kozikowski, whose previous research contributed to Pylarify and Pluvitco. The technology focuses on developing theranostic agents for metastatic castration-resistant prostate cancer, utilizing PSMA ligands for targeted therapy delivery.

According to market data, the Global PSMA PET Imaging Market reached $1.5 billion in 2022 and is projected to reach $2.0 billion by 2030. Pluvitco, a targeted radiopharmaceutical treatment, has a predicted market size of $2 billion.

Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) has successfully closed its previously announced underwritten public offering, raising $5.75 million in gross proceeds through the sale of 19,166,667 shares of common stock at $0.30 per share.

The company plans to utilize the net proceeds to fund its Phase II clinical trial for its lead product candidate, marketing and advertising services, and working capital. The offering was conducted on a firm commitment basis with WestPark Capital acting as the Sole Book-Runner.

Shuttle Pharma, founded in 2012 by Georgetown University Medical Center faculty members, focuses on developing radiation sensitizers to improve outcomes for cancer patients treated with radiation therapy (RT). Their mission aims to enhance cancer cure rates while limiting radiation side effects when used as primary treatment or in combination with other therapies.